CVRxCVRX
Recorded

CVRx Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

John YoungSenior Med Tech Analyst

Okay. How's that? Sounds good.

John YoungSenior Med Tech Analyst

Okay. All right. Good morning, everyone. Thank you for joining us for Canaccord Genuity's 2026 MedTech Diagnostics and Digital Health and Services Forum. My name is John Young, and I'm one of the med tech analysts here. I'm very pleased to be joined today by the management team of CVRx, Kevin Hykes, President and CEO, and John Landry, who officially stepped into the CFO role this week. John joined CVRx with more than two decades of med tech experience, including most recently as CFO of Nyxoah, and before that, 12 years at Vapotherm. For those less familiar with the story, CVRx is a Minneapolis-based commercial stage medical device company focused on neuromodulation solutions for patients with cardiovascular disease. Kevin, I want to start just with the Q3 results, and I think the call was pretty candid.

John YoungSenior Med Tech Analyst

You said that the headwinds are being more impactful and more persistent than anticipated, and 2026 revenue guidance has seen two consecutive cuts. Before we get into the specifics, could you step back and tell us what you got wrong in your assumptions coming into this year, and what is the single most important thing that has to go right for CVRx to return to consistent growth?

Kevin HykesPresident and CEO

Thank you, John. I appreciate it. Thank you for the chance to speak this morning. As it relates to Q3, and I guess even bigger picture in that week, I want to be really clear. We believe that this opportunity is absolutely intact. We have not underestimated the opportunity to significantly change the way that this disease is treated. What we did underestimate is the persistence and the magnitude of some of the headwinds we're facing in this market. Probably most obviously is our largest Medicare Advantage payer, whose behavior has changed dramatically over the last three quarters and gone from a 30-day approval rate in the mid-80s to now 12% as of the end of Q3. That was probably one of the most significant drivers of our revenue, revised guidance this quarter, and of the revenue we delivered.

Kevin HykesPresident and CEO

The second headwind that we did not fully anticipate or appreciate was this chronic understaffing in the field of heart failure. It's a small specialty to begin with, only 1,400 of these physicians, which is crazy given the size of the disease state, but there are fewer and fewer physicians entering the field, which has created almost a constant churn of job hoppers, which has tremendous destabilizing effects on a program that you're trying to build. We thought at one point that that was perhaps cyclical or seasonal or regional, but we're seeing this across the entire country. We're seeing it in our clinical trial interactions where we have principal investigators who committed to us in May that they would stick around for four years and be the principal investigator at Johns Hopkins, and they've already changed jobs, and the site isn't even yet enrolling patients.

Kevin HykesPresident and CEO

It's not going away. It's a structural issue. We are doing our best to mitigate it. I can talk about that further. The third piece of this is execution, and that we can control. The good news here is that we know what good looks like, and we've had pretty significant turnover as a result of this transformation, which was concentrated in four of our nine regions. In the five regions where we have experienced tenured teams and experienced leaders, and where we, through the metrics, know that they're running our playbook, we're seeing 20+% growth on average. In the four regions where the turnover is 80+% in the last 12 to 18 months, we're seeing a very different story. We know the strategy works.

Kevin HykesPresident and CEO

We know it can work even in the face of these headwinds, and we need to get those less tenured reps to the same place that their peers are and delivering on the strategy and treating patients day in and day out. The good news is, our tenure has never been higher, and our turnover is now at a two-year low. Those are obviously labile numbers that change, but we're happy with the trends we're seeing and the stability we brought to that team. Big picture, the dream's alive. It's about execution, because that's the element of those three that we can, in fact, control, and it's about putting the best defenses we can in place for the other two.

John YoungSenior Med Tech Analyst

Got it. I think we will jump into all those details. John, I want to ask you, because you have joined the company officially four weeks ago, CFO officially starting this previous week, but obviously you did a lot of diligence and fresh eyes coming into this opportunity. You are joining CVRx at a challenging moment, but clearly you had conviction to take this job. I would love to know what gives you that conviction. What do you see for CVRx?

John LandryCFO

Right. No, thank you very much, John, for the opportunity to be here and the very kind intro. When I looked at CVRx, I think overall, I am thrilled to be part of the CVRx team. I have followed the company for a period of time, and I really believe that we have a couple things going for us here at CVRx. We have a great technology. Barostim is a great technology. We have a very passionate, patient-focused team here at CVRx that is really put this patient in the front and center of everything we do. In addition, we participate in a very large market opportunity, a $10 billion total addressable market opportunity. We have best-in-class gross margins, and we have had historically 15% growth. I think right now, obviously, there is some near-term challenges that we need to work our way through.

John LandryCFO

But I think given the thing that really excited me in the diligence process was understanding that we had five of the regions, five of the nine regions that were driving 20+% growth. I think when we execute on our playbook and we have tenure in the sales organization, we can drive that double-digit growth, which I am excited about. Yes, while there will be some near-term challenges that we need to overcome, I am very confident that over the long term, we are going to be able to deliver long-term double-digit growth and be able to drive significant shareholder value for our organization.

John YoungSenior Med Tech Analyst

I know it is still early, but do you have any priorities for your first 100 days as CFO? Maybe could you give us a preview of maybe how you expect to change how CVRx builds its forecasts and sets guidance going forward?

John LandryCFO

Sure. Absolutely, John. I think over the next, say, 100 days or so, what I really want to do is dig into the business, learn the business, understand the key revenue drivers, understand all of the key inputs that really make the business move forward, and understand how we connect with customers and bring the technology into market. I want to understand all the levers we have in our P&L as well as our balance sheet. Then ultimately work with Kevin and the team to help drive adoption of Barostim into the marketplace. So that will be something I am looking at here in the first 100 days. In terms of forecasting, I think probably my historical experience is that generally it is focused in on the inputs. Inputs are very key in determining the outputs of the forecast.

John LandryCFO

I think understanding what those are, dialing those in, and making sure we have a good understanding of that so that we can extrapolate and forecast out the business going forward. I think that will be something I look at over the long term as we look into 2027. I think in the near term, the focus is, as we provided our guidance, we really took a look at the inputs that we could control. As we factored in guidance for the upcoming quarter, we took a look at making sure that we factored in all the key headwinds that Kevin alluded to earlier in developing that forecast.

John YoungSenior Med Tech Analyst

Got it. I think we will jump into just the MA headwinds that you guys are seeing. So the 30-day approval rate for UNH, which is your largest Medicare Advantage payer, has fallen to 12% from 83% in 2025. You said that they are denying every prior authorization at this point, and often the first three appeals as well. I know that the playbook today is to push denials to the administrative law judge until the payer writes the policy, and you did see some success there with Humana already. Have you reached an ALJ hearing yet for UNH yet, or when do you expect that to happen, and how many cases are in the pipeline?

Kevin HykesPresident and CEO

Yeah. So thank you. Maybe I will take that up one level first. The strategy is really twofold. The first is sort of strategically to engage at a policy level with each and every one of these Medicare Advantage payers, certainly the 10 big ones, and to encourage them to write policies on the basis of In this case, Humana, the number two Medicare Advantage provider in the country, has a written policy that allows us to go into United, Aetna, Cigna, et cetera, and say, "Look, the number two player is covering this. 100% of fee-for-service Medicare is covering this. You need to cover this for your beneficiaries." So it is sort of a top-down, bringing data and leverage and competitive pressure to bear to try to get them to write a policy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day